



Esperion Therapeutics, Inc.
 Investor Relations Department
 3891 Ranchero Drive
 Suite 150
 Ann Arbor, MI 48108
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: ESPR

Last Trade:	43.80
Trade Time:	4:00 PM ET Aug 23, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	9.40 - 57.38
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 11, 2017
[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Aug 9, 2017
[Esperion Prices Public Offering of Common Stock](#)
- Aug 8, 2017
[Esperion Announces Proposed Public Offering of Common Stock](#)
- Aug 8, 2017
[Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results](#)
- Aug 8, 2017
[Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 22, 2017
[Annual Report \(10-K\)](#)
- Mar 6, 2017
[Proxy Statement \(DEF 14A\)](#)
- Aug 8, 2017
[Quarterly Report \(10-Q\)](#)
- May 4, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016
[Quarterly Report \(10-Q\)](#)